Theriva Biologics Q2 net loss narrows on lower R&D costs, expenses

Theriva Biologics

11/08/2026 13:09

Overview
US cancer therapeutics developer's Q2 net loss narrowed yr/yr as expenses declined
Company dosed first patients in VIRAGE2 Phase 2a trial for metastatic pancreatic cancer
Cash and cash equivalents fell to $11.3 mln, with runway into Q1 2027

Outlook
Company expects to complete VIRAGE2 trial enrollment in H2 2026
Initial VIRAGE2 pharmacodynamic and safety data anticipated by Q3 2027
Company plans to discuss proposed retinoblastoma trial protocol with FDA in Q3 2026

Result Drivers
LOWER ADMINISTRATIVE EXPENSES - Co said Q2 general and administrative expenses fell mainly due to the absence of a prior-year contingent consideration adjustment related to a clinical trial milestone
REDUCED R&D COSTS - Q2 research and development expenses fell due to lower compensation and clinical trial costs for SYN-004 and SYN-020, partly offset by higher VCN-01 manufacturing and planning expenses

Company press release: ID:nGNX1hkJDp

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.07
 
Q2 Net Loss
 
$3.22 mln
 
Q2 loss from Operations
 
-$3.30 mln
 
Q2 Pretax Loss
 
$3.22 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Theriva Biologics Inc is $2.50, about 982.3% above its August 10 closing price of $0.23

Reuters Recommended Reads
Aug 11 - Upstream Bio Q2 net loss narrows slightly on lower R&D costs
Aug 10 - Biohaven Q2 net loss narrows on lower R&D spend
Aug 10 - Perspective Therapeutics Q2 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)